Skip to main content

Advertisement

SpringerLink
Log in

Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1–9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8–5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5–0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000. The mean hemoglobin level was 16.9 ± 2.2 g/dL for PV males and 15.5 ± 2.7 g/dL for PV females. Further analyses on hemoglobin levels showed the true positive rate of PV from the significantly elevated hemoglobin group (defined as >18.5 g/dL for men and >16.5 g/dL for women) was 3.01% and that of MPNs was 3.1%. Here, we provide the biggest population-based report on MPN epidemiology that can readily be used as a representative Asian data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951

    Article  CAS  PubMed  Google Scholar 

  2. Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F et al (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 89:581–587

    Article  PubMed  Google Scholar 

  3. Levine RL, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190–2198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J et al (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33:1199–1203

    Article  PubMed  PubMed Central  Google Scholar 

  5. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM et al (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118:401–408

    Article  CAS  PubMed  Google Scholar 

  6. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  CAS  PubMed  Google Scholar 

  7. Wadleigh M, Tefferi A (2010) Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 91:174–179

    Article  PubMed  Google Scholar 

  8. Kim DS (2010) Introduction: health of the health care system in Korea. Soc Work Public Health 25:127–141

    Article  CAS  PubMed  Google Scholar 

  9. Kim DS (2010) Special issue on the national health care system of South Korea. Soc Work Public Health 25:125–126

    Article  PubMed  Google Scholar 

  10. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289–297

    Article  PubMed  Google Scholar 

  11. Mehta J, Wang H, Iqbal SU, Mesa R (2014) Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 55:595–600

    Article  PubMed  Google Scholar 

  12. Phekoo KJ, Richards MA, Moller H, Schey SA, South Thames Haematology specialist Committee (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 91:1400–1404

    PubMed  Google Scholar 

  13. Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 189:121–132

    Article  CAS  PubMed  Google Scholar 

  14. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd (1994) Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 47:89–93

    Article  CAS  PubMed  Google Scholar 

  15. Roaldsnes C, Waage A, Nørgaard M, Ghanima W (2014) Epidemiology of myeloproliferative neoplasms in Norway. Blood 124:S634 (abstrac 1858)

    Google Scholar 

  16. Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:171–173

    Article  PubMed  Google Scholar 

  17. Srour SA, Devesa SS, Morton LM et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. Prepublished on April 7, 2016, as doi: 10.1111/bjh.14061

  18. Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Ki HY et al (2015) Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med 30:771–788

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS et al (2009) Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thromb Haemost 101:547–551

    CAS  PubMed  Google Scholar 

  20. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973–977

    Article  CAS  PubMed  Google Scholar 

  21. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45–52

    Article  CAS  PubMed  Google Scholar 

  22. Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T et al (2006) Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol 83:443–449

    Article  PubMed  Google Scholar 

  23. Bai J, Ai L, Zhang L, Yang F, Zhou Y, Xue Y (2015) Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol 90:1116–1121

    Article  CAS  PubMed  Google Scholar 

  24. Fu R, Xuan M, Lv C, Zhang L, Li H, Zhang X et al (2014) External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. Eur J Haematol 92:502–509

    Article  CAS  PubMed  Google Scholar 

  25. Kim JI (2013) Social factors associated with centenarian rate (CR) in 32 OECD countries. BMC Int Health HumRights 13:16

    Article  Google Scholar 

  26. Tefferi A (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83:491–497

    Article  CAS  PubMed  Google Scholar 

  27. Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know? Curr Hematol Malig Rep 9:340–349

    Article  CAS  PubMed  Google Scholar 

  28. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761

    Article  PubMed  Google Scholar 

  29. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65:132–139

    Article  CAS  PubMed  Google Scholar 

  30. Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R (2014) Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma 55:2368–2374

    Article  PubMed  Google Scholar 

  31. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901

    Article  CAS  PubMed  Google Scholar 

  32. Deadmond MA, Smith-Gagen JA (2015) Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol 141:2131–2138

    Article  PubMed  Google Scholar 

  33. Kim BJ, Heo C, Kim BK, Kim JY, Kim JG (2013) Effectiveness of gastric cancer screening programs in South Korea: organized vs opportunistic models. World J Gastroenterol 19:736–741

    Article  PubMed  PubMed Central  Google Scholar 

  34. Shim JI, Kim Y, Han MA, Lee HY, Choi KS, Jun JK et al (2010) Results of colorectal cancer screening of the national cancer screening program in Korea, 2008. Cancer Res Treat 42:191–198

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kang MH, Park EC, Choi KS, Suh M, Jun JK, Cho E (2013) The National Cancer Screening Program for breast cancer in the Republic of Korea: is it cost-effective? Asian Pac J Cancer Prev 14:2059–2065

    Article  PubMed  Google Scholar 

  36. Han MA, Choi KS, Lee HY, Jun JK, Jung KW, Kang S et al (2012) Performance of papanicolaou testing and detection of cervical carcinoma in situ in participants of organized cervical cancer screening in South Korea. PLoS One 7:e35469

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported by the National Health Insurance Service Ilsan Hospital Grant (NHIMC 2015-20-010). Also, this study used National Health Insurance Service National Sample Cohort (NHIS-NSC) data (NHIS-2016-1-114), made by the NHIS.

Authorship contributions

JMB, YJK, JY, and TSP designed the study concept, performed the research, analyzed the data, and wrote the manuscript; TY collected the data and maintained the database; JJY participated in designing the research; and all the authors approved the final version of the manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    Ja Min Byun

  2. Department of Laboratory Medicine, Kyung Hee University School of Medicine, 23, Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea

    Young Jin Kim & Tae Sung Park

  3. Research Institute, National Health Insurance Service Ilsan Hospital, Seoul, Republic of Korea

    Taemi Youk

  4. Yangpyeong Public Health Center, Yangpyeong, Republic of Korea

    John Jeongseok Yang

  5. Department of Laboratory Medicine, National Health Insurance Service Ilsan Hospital, 100, Ilsan-ro, Ilsandong-gu, Goyang, 10444, Republic of Korea

    Jongha Yoo

Authors
  1. Ja Min Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taemi Youk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Jeongseok Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jongha Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tae Sung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jongha Yoo or Tae Sung Park.

Ethics declarations

This study design was reviewed and approved by the Institutional Review Board of the National Health Insurance Service Ilsan Hospital (IRB No. NHIMC 2015-02-029).

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Ja Min Byun and Young Jin Kim contributed equally to this work.

Jongha Yoo and Tae Sung Park are co-correspondents for this work.

Electronic supplementary material

.

ESM 1

(DOCX 38 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Byun, J.M., Kim, Y.J., Youk, T. et al. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Ann Hematol 96, 373–381 (2017). https://doi.org/10.1007/s00277-016-2902-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2902-9

Keywords

Search

Navigation